Hepatic DisordersApril 9, 20265 min read

Everything You Need to Know About Primary sclerosing cholangitis for Step 1

Deep dive: definition, pathophysiology, clinical presentation, diagnosis, treatment, HY associations for Primary sclerosing cholangitis. Include First Aid cross-references.

Primary sclerosing cholangitis (PSC) is one of those Step diseases that looks deceptively simple (“beading on ERCP”) but hides a ton of high-yield connections—especially to ulcerative colitis and cholangiocarcinoma. If you can explain why PSC causes cholestasis, how it shows up in labs and imaging, and what it predisposes to, you’ll pick up easy points across GI, pathology, and even immunology.


What Is Primary Sclerosing Cholangitis (PSC)?

PSC is a chronic, progressive cholestatic liver disease characterized by inflammation, fibrosis, and stricturing of the intrahepatic and/or extrahepatic bile ducts.

Key Step framing:

  • Inflammation + fibrosis → multifocal bile duct strictures
  • Strictures → obstructed bile flow → cholestasis
  • Chronic injury → biliary cirrhosis + malignancy risk

Pathophysiology (What’s Actually Happening?)

PSC is thought to be immune-mediated (exact trigger unclear), strongly linked to IBD.

The core mechanism

  • Chronic bile duct inflammation (lymphocytic infiltrates)
  • Periductal concentric (“onion-skin”) fibrosis → narrowing/obliteration of ducts
  • Leads to:
    • Cholestasis (bile can’t get out)
    • Biliary cirrhosis over time
    • Ascending cholangitis risk due to stasis and bacterial overgrowth

The classic pathology buzzword

  • “Onion-skin” periductal fibrosis (very Step 1)
💡

First Aid cross-reference (GI—Hepatobiliary): PSC is typically listed under cholestatic patterns and biliary tract disease, emphasizing UC association, p-ANCA, beading, cholangiocarcinoma risk.


Epidemiology & High-Yield Associations

The big association: Ulcerative colitis

  • PSC is strongly associated with ulcerative colitis (more than Crohn).
  • Important nuance: PSC can occur even if UC symptoms are mild.

Antibodies

  • Often p-ANCA positive (not diagnostic, but classic)

Cancer risks (very testable)

PSC increases risk of:

  • Cholangiocarcinoma (major one)
  • Gallbladder carcinoma
  • Colorectal cancer (especially PSC + UC combo)
  • Hepatocellular carcinoma (via cirrhosis)

Board-style pearl: In a patient with PSC who develops worsening jaundice, weight loss, RUQ pain, or rising CA 19-9, think cholangiocarcinoma.


Clinical Presentation

Many patients are asymptomatic early

PSC is often found because of cholestatic labs on routine testing, especially in an IBD patient.

Symptoms when present

  • Fatigue
  • Pruritus (cholestasis)
  • Jaundice
  • RUQ discomfort
  • Intermittent fevers/chills if ascending cholangitis develops

Signs of chronic cholestasis/cirrhosis

  • Hepatomegaly, splenomegaly
  • Stigmata of chronic liver disease (late)
  • Fat-soluble vitamin deficiency (A, D, E, K) due to impaired bile delivery to gut

Labs: Recognize the Cholestatic Pattern

PSC typically shows a cholestatic liver enzyme pattern:

FindingExpected DirectionWhy it matters for Step
Alkaline phosphatase (ALP)↑↑Cholestasis marker (bile duct injury)
GGTHelps confirm hepatic source of high ALP
Bilirubin↑ (variable)May rise with progression/obstruction
AST/ALTMild ↑Not the dominant pattern

High-yield contrast:

  • PSC/PBC = cholestatic (ALP high)
  • Viral/ischemic/toxic hepatitis = hepatocellular (AST/ALT very high)

Diagnosis: Imaging Is the Money Shot

Best initial/confirmatory imaging (typical Step approach)

  • MRCP (noninvasive) or ERCP (invasive, also therapeutic)
  • Classic finding: “Beading” of the bile ducts due to alternating strictures and dilation

ERCP/MRCP hallmark:

  • Multifocal strictures + segmental dilationsbeaded appearance

Histology

Not always necessary if imaging is classic, but pathology is Step-relevant:

  • Periductal onion-skin fibrosis
  • Progressive duct obliteration → biliary cirrhosis

Typical clinical vignette

Young to middle-aged man with UC, pruritus, cholestatic labs, and beading on ERCP/MRCP.


PSC vs PBC (High-Yield Table)

These two are constantly compared on exams.

FeaturePSCPBC
Typical patientMan with UCMiddle-aged woman
Autoantibodiesp-ANCA (assoc.)AMA (anti-mitochondrial)
LocationIntra + extrahepatic ductsIntrahepatic ducts
ImagingBeading on MRCP/ERCPOften normal ducts; diagnosis by serology/biopsy
HistologyOnion-skin periductal fibrosisDestruction of intrahepatic ducts; granulomas sometimes noted
Cancer riskCholangiocarcinoma, gallbladder ca, CRCHCC via cirrhosis (less cholangioca emphasis)
Treatment themeManage cholestasis; transplant definitiveUrsodeoxycholic acid often used
💡

Step trap: Ursodeoxycholic acid is classically emphasized for PBC. In PSC, meds may improve labs/symptoms but do not reliably prevent progression—transplant is the definitive option for advanced disease.


Complications You Should Memorize

1) Cholangiocarcinoma

  • A top-tier PSC association
  • Suspect with systemic symptoms, worsening jaundice, RUQ pain, or rising tumor markers (e.g., CA 19-9)

2) Recurrent ascending cholangitis

  • Bile stasis predisposes to infection
  • Fever + RUQ pain + jaundice (Charcot triad) may show up

3) Cirrhosis and portal hypertension

  • Varices, ascites, splenomegaly (late)

4) Fat-soluble vitamin deficiency

  • Especially with long-standing cholestasis:
    • Vitamin K deficiency → ↑ PT/INR (bleeding tendency)

5) Increased colorectal cancer risk (PSC + UC)

  • This is high yield clinically and on exams:
    • PSC + UC = higher CRC risk than UC alone
    • Requires enhanced colon cancer surveillance in real life

Treatment (Step-Relevant, Reality-Based)

There is no proven medical therapy that reliably stops progression of PSC. Management focuses on symptoms, complications, and transplant when appropriate.

Symptom control

  • Pruritus:
    • Cholestyramine (bile acid sequestrant) is a classic choice
    • Rifampin or naltrexone may be used in practice (less Step-core)

Managing strictures and cholangitis

  • ERCP can be used to dilate dominant strictures and relieve obstruction
  • Antibiotics for ascending cholangitis (supportive detail)

Definitive therapy

  • Liver transplant for advanced disease
    • Indications include decompensated cirrhosis, recurrent cholangitis, intractable pruritus, etc.

High-yield point: Even after transplant, PSC can recur (less commonly tested, but worth knowing).


How PSC Shows Up in USMLE-Style Questions

Pattern recognition checklist

If you see:

  • UC history
  • Pruritus + fatigue
  • ALP >> AST/ALT
  • MRCP/ERCP beading → Answer is Primary sclerosing cholangitis

Common “next step” prompts

  • “Most likely diagnosis?” → PSC
  • “Most likely associated condition?” → Ulcerative colitis
  • “Most likely autoantibody?” → p-ANCA
  • “Most likely complication?” → Cholangiocarcinoma
  • “Most definitive treatment in advanced disease?” → Liver transplant

First Aid-Style Rapid Review (Ultra High-Yield)

  • PSC: inflammation + fibrosis of bile ducts → multifocal strictures
  • Association: Ulcerative colitis, p-ANCA
  • Imaging: ERCP/MRCP shows beading
  • Histology: onion-skin periductal fibrosis
  • Labs: cholestatic pattern (ALP↑)
  • Complications: cholangiocarcinoma, recurrent cholangitis, cirrhosis, CRC risk (esp with UC)
  • Treatment: symptom/stricture management; transplant is definitive